These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26993229)

  • 1. Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder.
    Akasaka T; Hokimoto S; Sueta D; Tabata N; Sakamoto K; Yamamoto E; Yamamuro M; Tsujita K; Kojima S; Kaikita K; Kajiwara A; Morita K; Oniki K; Saruwatari J; Nakagawa K; Ogata Y; Ogawa H
    Am J Physiol Heart Circ Physiol; 2016 Jun; 310(11):H1494-500. PubMed ID: 26993229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.
    Akasaka T; Sueta D; Arima Y; Tabata N; Takashio S; Izumiya Y; Yamamoto E; Yamamuro M; Tsujita K; Kojima S; Kaikita K; Kajiwara A; Morita K; Oniki K; Saruwatari J; Nakagawa K; Ogata Y; Matsui K; Hokimoto S
    Am J Physiol Heart Circ Physiol; 2016 Dec; 311(6):H1409-H1415. PubMed ID: 27663770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina.
    Akasaka T; Sueta D; Arima Y; Tabata N; Takashio S; Izumiya Y; Yamamoto E; Tsujita K; Kojima S; Kaikita K; Kajiwara A; Morita K; Oniki K; Saruwatari J; Nakagawa K; Hokimoto S
    Int J Cardiol Heart Vasc; 2017 Jun; 15():15-20. PubMed ID: 28616567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between cardiovascular risk factors and coronary microvascular dysfunction in cardiac syndrome X.
    Sestito A; Lanza GA; Di Monaco A; Lamendola P; Careri G; Tarzia P; Pinnacchio G; Battipaglia I; Crea F
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):322-7. PubMed ID: 21135582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease.
    Caliskan Z; Gokturk HS; Caliskan M; Gullu H; Ciftci O; Ozgur GT; Guven A; Selcuk H
    Microvasc Res; 2015 Jan; 97():25-30. PubMed ID: 25128749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease.
    Tona F; Serra R; Di Ascenzo L; Osto E; Scarda A; Fabris R; Montisci R; Famoso G; Tellatin S; Foletto M; Giovagnoni A; Iliceto S; Vettor R
    Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):447-53. PubMed ID: 24548662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease.
    Hokimoto S; Tabata N; Akasaka T; Arima Y; Kaikita K; Morita K; Kumagae N; Oniki K; Nakagawa K; Ogawa H
    J Cardiovasc Pharmacol; 2015 Feb; 65(2):148-52. PubMed ID: 25264752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary microvascular dysfunction is associated with higher frequency of thin-cap fibroatheroma.
    Dhawan SS; Corban MT; Nanjundappa RA; Eshtehardi P; McDaniel MC; Kwarteng CA; Samady H
    Atherosclerosis; 2012 Aug; 223(2):384-8. PubMed ID: 22766333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease.
    Sara JD; Widmer RJ; Matsuzawa Y; Lennon RJ; Lerman LO; Lerman A
    JACC Cardiovasc Interv; 2015 Sep; 8(11):1445-1453. PubMed ID: 26404197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of coronary microvascular function and nitric oxide synthase intron 4a/b polymorphism in patients with coronary slow flow.
    Ekmekci A; Güngör B; Özcan KS; Abaci N; Ilhan E; Ekmekci SS; Kemaloğlu T; Osmonov D; Ustek D; Eren M
    Coron Artery Dis; 2013 Sep; 24(6):461-7. PubMed ID: 23811833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between obstructive sleep apnea and coronary microcirculatory function among patients with cardiac syndrome X.
    Wang N; Li SB; Zhao LS; Li HY; Li ZJ; Shi QW; Li YF; Zhi Q
    Coron Artery Dis; 2014 Jan; 25(1):35-9. PubMed ID: 24217401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease.
    Recio-Mayoral A; Rimoldi OE; Camici PG; Kaski JC
    JACC Cardiovasc Imaging; 2013 Jun; 6(6):660-7. PubMed ID: 23643286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study.
    Cai N; Li C; Gu X; Zeng W; Zhong J; Liu J; Zeng G; Zhu J; Hong H
    BMC Cardiovasc Disord; 2023 Apr; 23(1):185. PubMed ID: 37024851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population.
    Yang YN; Wang XL; Ma YT; Xie X; Fu ZY; Li XM; Chen BD; Liu F
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):579-83. PubMed ID: 20460345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
    Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW
    Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.